Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033988 | 0.90 | PGR (0.52) | PGRARS1PR3SLC22A12RORC | |
| SCHEMBL3021238 | 0.88 | PGR (0.52) | PGRL3MBTL1KMT2AHSD17B10AR | |
| SCHEMBL3444933 | 0.88 | PGR (0.50) | PGRARS1PR3SLC22A12KCNH2 | |
| SCHEMBL3029375 | 0.85 | PGR (0.49) | PGRARRORCKCNH2 | |
| SCHEMBL3019921 | 0.78 | PGR (0.50) | PGRL3MBTL1KMT2AHSD17B10AR | |
| SCHEMBL3021063 | 0.78 | PGR (0.46) | PGRL3MBTL1ARSLC22A12RORC | |
| SCHEMBL3031759 | 0.78 | PGR (0.41) | PGRARSLC22A12KCNH2 | |
| SCHEMBL3025100 | 0.76 | PGR (0.46) | PGRARRORCKCNH2 | |
| SCHEMBL3029068 | 0.74 | PGR (0.37) | PGRARRORCKCNH2 | |
| SCHEMBL3031568 | 0.74 | PGR (0.52) | PGRARSLC22A12RORCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | PGR 1/4885L3MBTL1 4824/4885KMT2A 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.